Browsing Over 180 Presentations

Sort By
MSD - Advanced TNBC: Emerging landscape and treatment options Industry Satellite Symposia

Closing remarks (ID 333)

Lecture Time
18:25 - 18:30
Speakers
Session Name
MSD - Advanced TNBC: Emerging landscape and treatment options
Room
Channel 2
Date
Wed, 05.05.2021
Time
17:30 - 18:30
MSD - Advanced TNBC: Emerging landscape and treatment options Industry Satellite Symposia

Review of recent data with IO + Chemo (ID 330)

Lecture Time
17:45 - 18:00
Speakers
Session Name
MSD - Advanced TNBC: Emerging landscape and treatment options
Room
Channel 2
Date
Wed, 05.05.2021
Time
17:30 - 18:30
MSD - Advanced TNBC: Emerging landscape and treatment options Industry Satellite Symposia

Introduction and objectives (ID 328)

Lecture Time
17:30 - 17:35
Speakers
Session Name
MSD - Advanced TNBC: Emerging landscape and treatment options
Room
Channel 2
Date
Wed, 05.05.2021
Time
17:30 - 18:30
MSD - Advanced TNBC: Emerging landscape and treatment options Industry Satellite Symposia

Patient case study (ID 366)

Lecture Time
18:15 - 18:25
Speakers
Session Name
MSD - Advanced TNBC: Emerging landscape and treatment options
Room
Channel 2
Date
Wed, 05.05.2021
Time
17:30 - 18:30
MSD - Advanced TNBC: Emerging landscape and treatment options Industry Satellite Symposia

Overview of biomarker assays in advanced TNBC (ID 331)

Lecture Time
18:00 - 18:15
Speakers
Session Name
MSD - Advanced TNBC: Emerging landscape and treatment options
Room
Channel 2
Date
Wed, 05.05.2021
Time
17:30 - 18:30
Eisai Europe Ltd Industry Satellite Symposia

TBC (ID 369)

Lecture Time
17:30 - 17:50
Session Name
Eisai Europe Ltd
Room
Channel 1
Date
Wed, 05.05.2021
Time
17:30 - 18:30
MSD - Advanced TNBC: Emerging landscape and treatment options Industry Satellite Symposia

Unmet need in advanced TNBC (ID 329)

Lecture Time
17:35 - 17:45
Speakers
Session Name
MSD - Advanced TNBC: Emerging landscape and treatment options
Room
Channel 2
Date
Wed, 05.05.2021
Time
17:30 - 18:30
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Debating optimal neoadjuvant therapy (ID 336)

Lecture Time
19:30 - 19:40
Speakers
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Summary, final thoughts and live Q&A (ID 339)

Lecture Time
19:45 - 19:55
Speakers
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Individualizing therapeutic decision-making for patients with HR+/HER2- EBC (ID 337)

Lecture Time
19:05 - 19:15
Speakers
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Medical need to improve on standard therapies for HR+/HER2- EBC (ID 334)

Lecture Time
19:00 - 19:05
Speakers
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Future considerations on the horizon for HR+/HER2- EBC (ID 368)

Lecture Time
19:40 - 19:45
Speakers
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00